Paper39797461
Hypoxia-Responsive Covalent Organic Framework Nanoplatform for Breast-Cancer-Targeted Cocktail Immunotherapy via Triple Therapeutic Switch Mechanisms.
Huang G and 9 others. Small, 2025. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Hypoxia-Responsive Covalent Organic Framework Nanoplatform for Breast-Cancer-Targeted Cocktail Immunotherapy via Triple Therapeutic Switch Mechanisms. Papers, record 39797461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39797461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hypoxia-Responsive Covalent Organic Framework Nanoplatform for Breast-Cancer-Targeted Cocktail Immunotherapy via Triple Therapeutic Switch Mechanisms.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Metal-Organic Frameworks | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| Animals | |
| Female | |
| Xanthones | |
| Cell Line, Tumor | |
| Mice | |
| Tumor Microenvironment | |
| Reactive Oxygen Species |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2018-43 | Special Subsidy for Traditional Chinese Medicine Public Health Service | PubMed | ||
| 21874064 | National Natural Science Foundation of China | PubMed | ||
| 2023A1515012633 | Natural Science Foundation from Guangdong Science and Technology Department of China | PubMed | ||
| 201904010410 | Science and Technology Program of Guangzhou | PubMed | ||
| 110324220107245015 | Animal Ethics Committee of Southern Medical University | PubMed | ||
| 2018LZXNYD-YL04 | YangZhou Municipal Science and Technology Bureau | PubMed |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42889843 | Metal-Organic Framework-Based Nanomedicine for Sepsis Therapy: From Microenvironment Regulation to Precision Therapeutic Strategies. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42889843 | PubMed |
| 42846706 | Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy. | Biomater Res | 2026 | https://conductscience.org/library/papers/42846706 | PubMed |
| 42668618 | Porphyrin-copper (II) covalent organic framework nanoplatform with intrinsic bifunctional photodynamic and chemodynamic activities for synergistic multimodal cancer therapy. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42668618 | PubMed |
| 42363193 | Herb-derived immunometabolic modulators: traditional Chinese medicine at the crossroads of metabolism and antitumor immunity. | Chin Med | 2026 | https://conductscience.org/library/papers/42363193 | PubMed |
| 41814059 | Artificial intelligence-assisted spatial omics-based biomimetic nanoplatform for intelligent and precise intervention in the immunosuppressive core region of ovarian cancer. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41814059 | PubMed |
| 41799184 | Recent advances of metal-organic frameworks (MOFs) for drug delivery, cancer imaging and theranostics. | Theranostics | 2026 | https://conductscience.org/library/papers/41799184 | PubMed |
| 41322142 | Multifunctional DSF-loaded ICG-chelated nanozyme for four-in-one enhanced synergistic tumor therapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41322142 | PubMed |
| 40699734 | Biological Characteristics and Genomic Analysis of Acinetobacter nosocomialis Lytic Phage XC1. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40699734 | PubMed |
| 40285563 | Camouflaged Nanozymes with Oxidation-Promoting Activities Triggering Ferroptosis for Radio-Immunotherapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40285563 | PubMed |
| 39965148 | Reprogramming Lung Redox Homeostasis by NIR Driven Ultra-Small Pd Loaded Covalent Organic Framework Inhibits NF-κB Pathway for Acute Lung Injury Immunotherapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39965148 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CAT | 847 | PubTator's text mining | https://conductscience.org/library/genes/847 | NCBI Gene |
| HSP90AA1 | 3320 | PubTator's text mining | https://conductscience.org/library/genes/3320 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39797461
GET https://conductscience.org/api/papers/v1/39797461/authors